Mingshun Li

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

J. Ajani, Y. Janjigian, L. Wyrwicz, 2020 .

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

J. Ajani, T. Zander, M. Karamouzis, 2021, The Lancet.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

J. Ajani, T. Zander, M. Karamouzis, 2022, Nature.

LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study

J. Ajani, Y. Janjigian, L. Wyrwicz, 2021, Annals of Oncology.

Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

J. Ajani, Y. Janjigian, F. Franke, 2017 .

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.

J. Ajani, Y. Janjigian, L. Wyrwicz, 2021 .

CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.

J. Ajani, M. Karamouzis, Y. Janjigian, 2017 .

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

Y. Ba, Wen-Wei Hu, Wei Li, 2022, International journal of cancer.

Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649

J. Ajani, Y. Janjigian, L. Wyrwicz, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.